MARKET

MRNS

MRNS

Marinus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.54
+0.64
+4.03%
Pre Market: 16.54 0 0.00% 08:00 03/08 EST
OPEN
15.90
PREV CLOSE
15.90
HIGH
16.59
LOW
15.19
VOLUME
6
TURNOVER
--
52 WEEK HIGH
17.14
52 WEEK LOW
4.160
MARKET CAP
588.42M
P/E (TTM)
-4.8206
1D
5D
1M
3M
1Y
5Y
The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings
Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA...
Benzinga · 1d ago
Fragile X Syndrome Market 2021 Strategic Plans by Globally Industry Demand, On Going Trends, Regional Overview, Top Manufacture, Business Growth and Forecast to 2027, Says Industry Research Biz
The Express Wire · 6d ago
Ganaxolone – Emerging Insight and Market Forecast – 2030
Feb 26, 2021 (Heraldkeepers) -- Overview"Ganaxolone – Emerging Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of...
Heraldkeepers · 02/26 08:42
Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today unveiled its new brand identity rooted in the company's guiding principles of commitment, ...
BusinessWire · 02/23 12:00
Marinus Pharmaceuticals to Participate in Multiple Investor Healthcare and Life Sciences Conferences
Marinus Pharmaceuticals will participate in multiple investor healthcare and life sciences conferences.
Business Wire · 02/17 12:00
What Kind Of Shareholders Own Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)?
If you want to know who really controls Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ), then you'll have to look at the...
Simply Wall St. · 02/15 06:57
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marinus today announced the grant of inducement awards to five new employees.
Business Wire · 02/12 21:01
Marinus Pharmaceuticals to Provide Business Update and Announce Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
Marinus Pharmaceuticals will release the financial results for the fourth quarter and fiscal year ended December 31, 2020 on March 9 via webcast.
Business Wire · 02/10 12:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRNS. Analyze the recent business situations of Marinus Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRNS stock price target is 28.44 with a high estimate of 35.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 165
Institutional Holdings: 43.09M
% Owned: 121.12%
Shares Outstanding: 35.58M
TypeInstitutionsShares
Increased
37
5.89M
New
37
1.87M
Decreased
14
1.06M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Nicole Vitullo
President/Chief Executive Officer/Director
Scott Braunstein
Chief Financial Officer
Edward Smith
Vice President/General Counsel/Secretary
Martha Manning
Vice President/Director of Investor Relations
Sasha Damouni Ellis
Other
Joseph Hulihan
Other
Christy Shafer
Director
Charles Austin
Independent Director
Enrique Carrazana
Independent Director
Michael Dougherty
Independent Director
Elan Ezickson
Independent Director
Seth Fischer
Independent Director
Timothy Mayleben
No Data
About MRNS
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Webull offers kinds of Marinus Pharmaceuticals Inc stock information, including NASDAQ:MRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNS stock methods without spending real money on the virtual paper trading platform.